Answer
In clinical studies of patients with non-Hodgkin's lymphoma, adding rituximab to a mobilisation regimen of plerixafor and G-CSF did not affect patient safety or CD34+ cell yield.
Sources for this answer
- Plerixafor Seacross 20 mgml solution for injectionSeacross Pharmaceuticals Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 2Document updated
Sources checked